

Fig. 1. HHV-8 and vaccinia virus detection using Viro-Adembeads. (A) Copies of HHV-8. (B) Copies of vaccinia virus. The y-axis indicates copy numbers of the virus in 1% of the extracted DNA. 'UL' indicates 'under limitation'. 'Dilution' and 'Input' under the x-axis indicate dilution factors and 1% of the virus copy numbers in 1 mL of each sample, respectively. (C) Recovery rates. Virus solutions were diluted  $\times 10$  with beverages; viruses were then recovered with Viro-Adembeads. Recovery rates were calculated based on the results of real-time PCR. Error bars indicate standard deviations.




Fig. 2. Green tea and orange juice reduce the efficiency of vaccinia virus infection. (A) Microscopic view of plaques. (B) Numbers of plaque by vaccinia virus. Error bars indicate standard deviations.

media. Vaccinia virus was also recovered at low rates in all beverages. In both viruses, the recovery rates differed among beverages. For example, the recovery rates in milk, orange juice, and green tea were significantly lower than that in water. These results indicate that the efficiency of virus detection depends on the kind of beverage being tested.

To know whether the beverage type affects viral infectivity, we examined a plaque assay using vaccinia virus in the beverages, because it is difficult to perform a plaque assay in HHV-8 (7). Virus solution containing 10,000 plaque-forming units (pfu) was mixed with 1 mL of each beverage and incubated with rotation for 20 min. From these solutions, 100- $\mu$ L samples were added to CV-1 cells with 1 mL of serum-free medium per well in a 6-well plate. The plaque assay showed that the number of plaques was dramatically reduced in green tea and orange juice (Figure 2). The plaque number in barley tea did not change from that of water and milk. These results suggested that green tea and orange juice reduced the infectivity of vaccinia virus. The pH conditions of the water, milk, orange juice, and green tea used in this experiment were pH 7.2, 6.8, 4.0, and 6.2, respectively, suggesting that acidity is not the only factor in reducing virus infectivity.

The results in the present study suggest that the type of

beverage affects virus detection in virus-contaminated beverages and that Viro-Adembeads would be a useful tool for virus detection in virus-contaminated beverages. Our results clearly demonstrated that orange juice and green tea reduced virus infectivity of vaccinia virus. One of the reasons could be a low pH in orange juice, but other factors were unveiled. We checked pH conditions of several kinds of orange juice in a food store and found they ranged from pH 3.3 to pH 4.2, suggesting that the orange juice used in the present study was not special, at least with regard to its pH condition. Incubation of viruses with orange juice or green tea reduced not only the number of plaques in a plaque assay but also the copy numbers of the virus detected by a real-time PCR after virus collection, suggesting that orange juice and green tea affect the binding efficiency of viruses to Viro-Adembeads, in addition to reducing virus infectivity. No plaque was observed in any well of CV-1 cells with 10,000 pfu of vaccinia virus incubated with orange juice or green tea. On the other hand, we could detect the viruses from orange juice or green tea containing the same amount of viruses by Viro-adembeads and real-time PCR, although the recovery rate was low. These data indicated that Viro-adembeads and real-time PCR was more sensitive for detecting vaccinia virus in orange juice

and green tea than was the plaque assay.

The use of Viro-Adembeads is an easy method for collecting viruses from a virus-contaminated liquid. One of the merits of this method is its rapidity. In our experiment, it took about 30 min to collect viruses from virus-contaminated beverages, which is much quicker than the using the ultracentrifuge method. Another merit is that Viro-Adembeads can be used in liquid samples with some precipitation and turbidity, like milk and orange juice. Such precipitation and turbidity interfere with efficient isolation of viruses in any method using an ultracentrifuge. In addition, the use of Viro-Adembeads does not require any machine. Thus, although further studies are required to determine optimal techniques and conditions, Viro-Adembeads could be a useful tool for rapidly detecting viruses in virus-contaminated beverages.

#### ACKNOWLEDGMENTS

This study was supported by the Health and Labour Sciences Research Grants on Emerging and Re-emerging Infectious Diseases (to TS, No. H20-Shinko-Ippan-006) from the Ministry of Health, Labour and Welfare of Japan; and a grant for Research on Publicly Essential Drugs and Medical

Devices from the Japan Health Sciences Foundation (to HK and TS, No. SAA4832).

#### REFERENCES

1. Sakudo, A., Baba, K., Tsukamoto, M., et al. (2009): Anionic polymer, poly(methyl vinyl ether-maleic anhydride)-coated beads-based capture of human influenza A and B virus. *Bioorg. Med. Chem.*, 17, 752-757.
2. Sakudo, A. and Ikuta, K. (2008): Efficient capture of infectious H5 avian influenza virus utilizing magnetic beads coated with anionic polymer. *Biochem. Biophys. Res. Commun.*, 377, 85-88.
3. Morikawa, S., Sakiyama, T., Hasegawa, H., et al. (2005): An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. *J. Virol.*, 79, 11873-11891.
4. Renne, R., Zhong, W., Herndier, B., et al. (1996): Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. *Nat. Med.*, 2, 342-346.
5. Asahi-Ozaki, Y., Sato, Y., Kanno, T., et al. (2006): Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases. *J. Infect. Dis.*, 193, 773-782.
6. White, I.E. and Campbell, T.B. (2000): Quantitation of cell-free and cell-associated Kaposi's sarcoma-associated herpesvirus DNA by real-time PCR. *J. Clin. Microbiol.*, 38, 1992-1995.
7. Fedorko, D.P., Preuss, J.C., Fahlc, G.A., et al. (2005): Comparison of methods for detection of vaccinia virus in patient specimens. *J. Clin. Microbiol.*, 43, 4602-4606.

## High Molecular Weight Form of Adiponectin in Antiretroviral Drug-induced Dyslipidemia in HIV-Infected Japanese Individuals Based on *in vivo* and *in vitro* Analyses

Rumi Minami, Masahiro Yamamoto, Soichiro Takahama, Hitoshi Ando, Tomoya Miyamura and Eiichi Suematsu

---

### Abstract

---

**Objective** High molecular weight (HMW)-adiponectin has been found to be a better negative regulator of insulin resistance than total adiponectin. The aim of this study was to investigate the influence of HMW-adiponectin on antiretroviral therapy (ART)-induced dyslipidemia in Japanese human immunodeficiency virus (HIV)-infected individuals. We also examined the effect of some antiretroviral drugs (ARVs) on adipocytes *in vitro*.

**Patients and Methods** Fifty-seven HIV-infected patients were enrolled in four clinical groups; (I) patients who started ART containing efavirenz (EFV); (II) patients who started ART containing a protease inhibitor without atazanavir (ATV); (III) patients who started ART containing ATV; (IV) patients who switched from ART without ATV into ART containing ATV. We measured the serum HMW-adiponectin before and one year after starting or changing ART, using an enzyme-linked immunosorbent assay (ELISA). Furthermore, we treated the mouse adipocytes (3T3-L1) with some ARVs. The lipid content was assessed using Oil Red O staining. The expression of adiponectin was measured by quantitative real-time PCR.

**Results** The serum HMW-adiponectin decreased significantly in groups (I) and (II) after starting ART, and increased significantly in group (IV) after changing from ART without ATV to ART with ART. EFV, ritonavir (RTV) and nelfinavir (NFV) inhibited the expression of adiponectin mRNA in mature 3T3-L1 and to a greater extent in pre-mature 3T3-L1. This phenomenon was reversible when ARV was changed to ATV.

**Conclusion** Effects of the ARVs on adiponectin may vary depending on the administration of different drugs. These data suggest that the distinct metabolic effects of ARV could therefore be a consequence of their differential effects on the production of adiponectin.

**Key words:** HMW-adiponectin, antiretroviral therapy, dyslipidemia

(Inter Med 48: 1799-1875, 2009)

(DOI: 10.2169/internalmedicine.48.2340)

---

### Introduction

---

Adiponectin is an adipokine secreted exclusively by adipocytes: this protein plays an important role in the control of systematic lipid metabolism and insulin sensitivity (1). Adiponectin forms multimers and is present in the serum as a trimer, hexamer, or as a high molecular weight (HMW) form (2). The HMW isoform most avidly binds to its recep-

tors and stimulates AMP-activated protein kinase, one of the key molecules mediating the metabolic actions of adiponectin.

Antiretroviral therapy (ART) has prolonged survival in human immunodeficiency virus (HIV)-infected individuals, but most individuals receiving ART develop metabolic abnormalities, which include dyslipidemia (elevated plasma triglycerides and cholesterol), increased visceral and dorsocervical adipose tissue and peripheral lipoatrophy (3). Although

HIV infection itself (4) and nucleoside reverse transcriptase inhibitors (NRTI) (5-7) have been associated with metabolic abnormalities, there are increasing clinical and epidemiological data that suggest a central role for HIV protease inhibitors (PIs) in the causation of metabolic complications (8) and atazanavir (ATV) use has been associated with a decrease in hyperlipidemia, less insulin resistance and reversal of lipodystrophy (9).

Several recent clinical studies suggest that hypoadiponectinemia might play an important role in the causation of metabolic abnormalities associated with HIV infected individuals treated with PI-based ART, especially for those with lipodystrophy (8, 10, 11), but to date, limited data have been published whether this hypoadiponectinemia is due to a disturbance of adipocyte differentiation, or to the decrease in the number of adipose cells number, or a dysfunction of adipocytes. In addition, there are still no data regarding the influence of antiretroviral drugs (ARVs) on serum HMW-adiponectin levels in Japanese, about 40% of whom have a genetic variation in the adiponectin gene associated with a reduced adiponectin level (12).

This study compared the effect on HMW-adiponectin level between ATV, PIs (except for ATV), ATV replacement therapy and non-nucleoside reverse transcriptase inhibitors (NNRTI), efavirenz (EFV) in HIV-infected Japanese subjects. In addition, the influence of each of the ARVs on adipocyte development and the expression of adiponectin were evaluated, using in vitro models.

---

## Materials and Methods

---

### Study population

The subjects evaluated in this study consisted of 57 HIV-positive patients admitted to National Hospital Organization Kyushu Medical Center, who started ART or were changing the ART combination. The present study was conducted in accordance with the regulations of the institutional ethics committee. These individuals were enrolled into four clinical groups; (I) patients who started ART containing EFV; (II) patients who started ART containing PIs without ATV; (III) patients who started ART containing ATV; (IV) patients who replaced the ART without ATV into ART containing ATV. The Body Mass Index (BMI), serum triglyceride, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, HMW adiponectin were measured before and one year after starting or changing ART. HMW-adiponectin was measured by enzyme-linked immunosorbent Assay (ELISA), using the Human Adiponectin ELISA kit for Total and Multimers (Daiichi Pure Chemicals Co., Tokyo, Japan). Lipodystrophy was determined by a standardized, lipodystrophy-specific physical examination which recorded lipodystrophy and/or diffuse fat accumulation in the face, neck, dorsocervical spine, arms, breasts, abdomen, buttocks and legs.

### Cells

The 3T3-L1 cells were purchased from the Japanese Collection of Research Bioresources. The cells were maintained in DMEM supplemented with 10% fetal bovine serum. For differentiation, post confluent cells were induced by incubation with 0.5 mM 3-isobutyl-methylxanthine and 1  $\mu$ M dexamethasone for 2 days. This is followed by incubation with 10  $\mu$ g/mL insulin for 2 days. The cells were then maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS) for another 2 days. To investigate the effects of ARVs on adipogenesis, and to investigate the difference between the effect of ARVs on preadipocytes and the effect on mature adipocytes, several ARVs were added to the medium before and after differentiation of 3T3-L1 cells.

### Antiretroviral drugs

Efavirenz (EFV), ritonavir (RTV), nelfinavir (NFV) were purchased from Toronto Research Chemicals Inc. (Ontario, Canada). ATV was provided by Bristol-Myers Squibb Company (NY, USA). Drug stocks in dimethyl sulfoxide (DMSO) were stored at -20°C and diluted into culture media. Vehicle control incubations received the same final DMSO concentration as all drug-treated incubations (0.1%). The IC<sub>50</sub>/IC<sub>95</sub> and the C<sub>max</sub> of each drug are as follows; EFV (IC<sub>95</sub>=1.7-25nM, C<sub>max</sub>= 14.2-28.8  $\mu$ M), RTV (IC<sub>50</sub>=65-289nM, C<sub>max</sub>= 0.84-21.9  $\mu$ M), NFV (IC<sub>50</sub>=30-60nM, C<sub>max</sub>= 5.0-8.6  $\mu$ M), and ATV (IC<sub>50</sub>=2-5nM, C<sub>max</sub>=4.96-8.38  $\mu$ M). The cells were treated with 20  $\mu$ M of EFV, RTV and ATV and 10  $\mu$ M of NFV.

### Quantitative real time RT-PCR

Total cellular RNA was isolated from 3T3-L1 cells, using QIAamp RNA Blood Mini (QIAGEN, Tokyo, Japan), including treatment with DNase. cDNA was generated from the RNA using TAKARA RNA PCR kit (TAKARA BIO, Shiga, Japan). Real time PCR was conducted with the LineGene33 (BioFlux, Tokyo, Japan) using SYBR Green Realtime PCR Master Mix (TOYOBO Co, Osaka, Japan). As an internal control measurement, to normalize for input DNA, copy numbers of  $\beta$ -actin were determined in every sample tested. The ratio of the normalized mean value for drug-treated samples was calculated and is given in the graphs.

### Measurement of adiponectin levels in culture medium

The secretion of adiponectin from 3T3-L1 cells were determined by measuring the adiponectin concentration of culture medium, using the Mouse Adiponectin/Acrp30 Immunoassay (R&D systems, Minneapolis, USA).

### Oil Red O staining

The cellular lipid content was assessed by lipid staining with Oil Red O. Staining was quantified at 520 nm after

Table 1. Characteristics of 57 HIV-infected Individuals and the Changes of Metabolic Markers

	group I	group II	group III	group IV (pre)	group IV (post)
Number of cases (M/F)	15 (13/2)	14 (13/1)	14 (13/1)	14 (12/2)	
Mean age (SD) (years)	37.7 (10.8)	42.1 (14.2)	38.3 (9.1)	46.1 (12.6)	
NRTI combination (number)(frequency %)					
Abacavir/ lamivudine	0 (0)	0 (0)	1 (7.1)	0 (0)	2 (14.3)
Zidovudine/ lamivudine	4 (26.7)	0 (0)	4 (28.6)	5 (35.7)	4 (28.6)
Stavudine/ lamivudine	7(46.7)	7 (50)	5 (35.7)	6 (42.9)	4 (28.6)
Didanosine/ lamivudine	0 (0)	0 (0)	0 (0)	2 (14.3)	2 (14.3)
Didanosine/ zidovudine	0 (0)	2 (14.3)	0 (0)	0 (0)	0 (0)
Tenofovir/ emtricitabine	4 (26.7)	5 (35.7)	4(28.6)	1 (7.1)	2 (14.3)
the ratio of after to before starting or changing ART [mean (SE)]					
Body Mass Index	1.00 (0.01)	0.99 (0.01)	1.02 (0.01)	0.98 (0.04)	
Tryglyceride	1.63 (0.19)*	1.72 (0.24)*	1.22 (0.17)	1.00 (0.304)	
HDL-cholesterol	1.29 (0.12)*	1.17 (0.16)	1.14 (0.11)	1.01 (0.07)	
LDL-cholesterol	1.17 (0.12)	1.27 (0.12)*	1.10 (0.05)	0.85 (0.06)	
HMW-adiponectin	0.61 (0.24)*	0.65 (0.09)*	1.19 (0.20)	1.61 (0.11)	

P values are evaluated by one sample sign test. \* indicates significant difference (\* p<0.001, \*\* p<0.05)

NRTI, nucleotide reverse transcriptase inhibitor; ART, antiretroviral therapy

"pre" indicates before changing ART, and "post" indicates after changing ART.

solubilization, using an Adipogenesis Assay Kit (Chemicon International Temecula, CA, USA)

### Statistical analysis

To evaluate the changes of BMI, serum triglyceride, LDL-cholesterol, HDL-cholesterol, HMW-adiponectin after starting or changing ART, the one sample sign test was applied. The Mann-Whitney test was used to compare the serum HMW-adiponectin according to lipodystrophy. In vitro experiments were reproduced in at least three independent experiments. The results are presented as the mean  $\pm$  SD. Significance was determined as described in the figure legends.

## Results

### The effect of ARV on the lipid profile and HMW adiponectin

The demographic and clinical characteristics for the 57 patients included in the study are shown in Table 1. There were no significant differences in the age and the NRTI combinations used as the backbone of PIs or EFV among the four groups ( $\chi$ -square test). The serum triglycerides and LDL-cholesterol increased significantly in individuals in groups I and II and LDL-cholesterol decreased significantly in individuals with group IV. The serum HMW-adiponectin decreased significantly in individuals in groups I and II and increased significantly in individuals with group IV. On the other hand, there was no change in the triglyceride, LDL-cholesterol, and HMW-adiponectin levels in individuals in group III (Table 1). These results show that serum HMW-adiponectin level decreased in individuals with ART including EFV or PIs except ATV, but the decrease was reversible and it was recovered by changing the ART into that including ATV.


### HMW-adiponectin and lipodystrophy

The development of lipodystrophy was observed in 14 of the 43 patients who newly initiated ART (the patients of groups I, II, and III). Lipodystrophy was more prevalent in

group I (53.3%) and group II (28.6%) than in group III (14.3%). The differences in lipodystrophy were not driven by the overall weight gain. There was no significant difference in the serum HMW-adiponectin before ART between individuals with and without lipodystrophy followed by ART, but the serum HMW-adiponectin after starting ART and the ratio of HMW-adiponectin after to before starting ART decreased significantly in individuals with lipodystrophy (Fig. 1).

### The effect of ARV on adiponectin mRNA levels in differentiating 3T3-L1 cells

As shown in Table 1, the effect of ART on dyslipidemia and lipodystrophy differed among the ART menus, but it is nearly impossible to fully separate the effects of the drug classes in the clinical data, because the patients received a combination of several classes of ART. As a result, *in vitro* models were used to examine the precise influence of these drugs on adipocyte development or metabolism, using well-characterized preadipocyte 3T3-L1 cells. The concentrations of ARVs used in this assay were within the range (RTV, EFV) or a little higher (ATV, NFV) than what is generally observed in plasma from individuals receiving therapeutic doses of ARV. Considering that some ARVs can accumulate in fat tissue, it is possible that the effects of ARVs on 3T3-L1 cell lines observed *in vitro* may also occur *in vivo*. When pre-adipocytes were treated with ARV, lipid accumulation was severely reduced by EFV and NFV (Fig. 2A). The adiponectin mRNA level was reduced by RTV, EFV, NFV, and was not affected by ATV (Fig. 2B). Similar results were obtained concerning the secretion of adiponectin into the culture medium (Fig. 2C). Since it is possible that the effect of ARV on the adipocyte metabolism is known to differ between preadipocytes and mature adipocytes, the mature adipocytes were also treated with ARVs. Mature adipocytes were less sensitive to ARVs' effects on lipid accumulation and adiponectin mRNA level than premature adipocytes. Lipid accumulation was reduced by EFV, RTV and NFV (Fig. 2A). The adiponectin mRNA level was reduced by RTV, EFV, and NFV, whereas ATV did not affect the adi-



**Figure 1.** The levels of serum HMW-adiponectin in HIV-infected individuals with/without lipodystrophy. (A) HMW-adiponectin before starting ART, (B) HMW-adiponectin after starting ART, (C) the ratio of HMW-adiponectin after starting ART to that before starting ART. The medians are indicated with horizontal bars. The vertical bars indicate the range between 10% and 90% and the horizontal boundaries of the boxes represent the interquartile range. P values are evaluated by the Mann-Whitney U-test. \*  $p < 0.01$ , \*\* $p < 0.05$  versus individuals without lipodystrophy. LD: lipodystrophy

adiponectin mRNA level (Fig. 2B). Similar results were obtained concerning the secretion of adiponectin into the culture medium (Fig. 2C).

#### **The effect of changing PI/EFV to ATV on adiponectin mRNA levels in 3T3-L1 cells**

In the clinical study, the decreased adiponectin induced by PI/EFV was restored by switching the drugs to ATV. In addition, the precise effect of ATV on decreased adiponectin mRNA induced by PI/EFV was examined in vitro, using 3T3L1 cells. Adiponectin mRNA recovered significantly in mature adipocytes after switching drugs from EFV and NFV to ATV, but it did not recover on EFV- and NFV-treated pre-adipocytes and RTV-treated pre- and mature adipocytes (Fig. 3).


## **Discussion**

Several studies have reported that metabolic syndrome is more common in subjects with HIV infection than in HIV-negative individuals. Although uncontrolled HIV replication can cause an adverse modification of the lipid metabolism, these modifications can be mainly induced by ART. The present study described the lipid abnormalities and lipodystrophy associated with ART. Hypertriglyceridemia was more common than abnormalities of HDL cholesterol and LDL cholesterol. LDL cholesterol increases were only observed in the population of group II (PI without ATV). These abnormalities were recovered by changing ART to the ATV containing regimen. In HIV-negative populations, the most common features associated with metabolic syndrome are obesity and hypertension. On the other hand, in HIV-positive populations, hypertriglyceridemia and hypertension are reported to be common components and the most frequent abnormalities that lead to metabolic syndrome (3).

That is why HIV-positive patients might need to have their ART regimen tailored to their lipid abnormalities.

In this study, we also investigated the effect of ARVs on serum HMW-adiponectin, which has been reported to be a useful marker for evaluating insulin resistance and metabolic syndrome. This is the first study to investigate the influence of ARVs on the serum HMW-adiponectin levels in Japanese HIV-infected individuals. In general, the serum adiponectin levels are known to be inversely related to the adipose tissue mass (13). The serum adiponectin levels have been reported to rise when obese persons lose weight (14). We showed that adiponectin levels are relatively low in HIV-infected individuals with lipodystrophy who have a low fat mass, and this is consistent with previous reports (7, 10). These results suggest that the normal relationships between adiponectin concentration and adipose droplets appear to be lost or reversed in HIV-infected individuals. Since adiponectin expression is higher in subcutaneous fat than in visceral fat in humans (15), visceral fat accumulation and subcutaneous fat loss may thus lead to decreased adiponectin production both in lipoatrophic and lipohypertrophic patients. Therefore, fat redistribution may actually be responsible for the decreased adiponectin levels in HIV patients with lipodystrophy. As shown in Fig. 1(C), it is certain that some of the patients without lipodystrophy had a decrease in serum HMW-adiponectin levels, but these patients had dyslipidemia more frequently than the patients with either normal or high serum HMW-adiponectin without lipodystrophy (data not shown). Considering the fact that clinical HIV lipodystrophy has been reported to be associated with dyslipidemia, these patients might thus have the potential to be complicated by lipodystrophy. Therefore, the low levels of serum HMW-adiponectin are correlated with lipodystrophy and/or dyslipidemia induced by PIs and NNRTI (EFV).

The present study also showed the direct effects of ARVs



**Figure 2.** The effect of ARV in pre-adipocytes and mature adipocytes. From confluence (day 0), 3T3-L1 cells were treated with differentiation medium in the absence (control) or in the presence of vehicle or various ARVs. To compare the effects of ARVs on preadipocytes with mature adipocytes, ARVs were added to the medium on day 0, when 3T3-L1 cells are still preadipocytes (gray bar) or on day 6, when 3T3-L1 cells differentiate to mature adipocytes (white bar). (A) The effects of ARVs on triglyceride accumulation during 3T3-L1 adipose conversion. On day 7, the cells were stained with Oil red O. Staining was quantified at 520 nm after solubilization and expressed as  $\% \pm SE$  of the control on day 7. (B) The effect of ARV on adiponectin mRNA levels in 3T3-L1 cells. On day 7, total RNA was prepared and mRNA levels were determined by real time RT-PCR. The results shown are after correction for the levels of  $\beta$  actin mRNA and normalized to the controls and represent the mean  $\pm SE$ . (C) The effect of ARV on adiponectin secretion in 3T3-L1 cells. At day 7, each supernatant was collected. Then, concentrations of the adiponectin were determined using an ELISA. Results shown are normalized to the controls and represent the mean  $\pm SE$ . Significance of difference between vehicles and other ARVs was evaluated by using the Dunnett test. EFV: efavirenz, RTV: ritonavir, ATV: atazanavir, NFV: nelfinavir

on the expression of adiponectin mRNA. In 3T3-L1 cells, the expression of adiponectin mRNA was decreased by RTV, NFV and EFV, but not by ATV. These data are consistent with our *in vivo* data. The pre-mature adipocytes were more sensitive to the effect of NFV and EFV on adiponectin mRNA and lipid accumulation than mature adipocytes.


Since adiponectin is mainly produced from mature adipocytes, some factors, such as the regulatory mechanisms for the differentiation of adipocytes, might be involved in the expression of adiponectin. In fact, in subcutaneous fat from individuals from HIV-associated lipodystrophy, decreased expression of some differentiation-associated gene, such as sterol regulatory element binding protein 1, CAAT enhancer binding protein  $\alpha$ , and peroxisome proliferators-activated receptor- $\gamma$  have been described (16). On the other hand, the effects of RTV and ATV on the expression of adiponectin mRNA and lipid accumulation were not significantly different between pre-mature adipocytes and mature adipocytes. Further, the effects of RTV, NFV, and EFV on adiponectin expression were observed also in mature adipocytes, though to a lesser extent than in NFV- and EFV-treated pre-mature adipocytes. These results showed some mechanisms other than differentiation-associated gene might be involved in the expression of adiponectin. Adipose cells are highly sensitive to oxidative stress, and it has been reported that oxidative stress is one of the mechanisms that regulates adiponectin expression. Using a reporter construct containing the adiponectin promoter, reactive oxygen species (ROS) have been shown to reduce the transcriptional activity of the adiponectin gene in 3T3-L1 adipocytes (17). From the current data, it is certain that various mechanisms are involved in the regulation of adipokine expression and that the effects of ARVs on adipogenesis and adiponectin expression may vary among different drugs. The distinct metabolic effect of ARVs could therefore be a consequence of their differential effects on both the production of adiponectin and the adipocyte physiology.

We have shown that ATV, in comparison to RTV, NFV and EFV, causes less inhibition of adiponectin secretion and lipid accumulation. Furthermore, the replacement of RTV, NFV, and EFV to ATV did not decrease the serum HMW adiponectin level and ATV replacing therapy has been associated with a decrease in hyperlipidemia and an increase in serum HMW adiponectin in HIV-infected patients. In the same way, ATV leads to a reversal in the impairment of adiponectin secretion or other metabolic abnormalities in 3T3-L1 cells. These properties could underlie the favorable metabolic side effect profile of ATV observed in its clinical use.

This study showed the direct effect of ARV on the lipid metabolism, but it is possible that such abnormalities in adiponectin and lipid metabolism in HIV-infected individuals are the result of either the consequence of HIV infection itself or of cytokine/chemokine released from infiltrating macrophages, or several other factors.

This study provides important new information for clinicians and patients regarding the relative risk and benefits of available antiretroviral regimens for the initial therapy of HIV-1 infection. EFV and some PIs except for ATV containing ART decreased serum HMW-adiponectin, which is associated with dyslipidemia and lipodystrophy. Some ARVs, with the exception for ATV decreased the expression of adiponectin in adipocytes *in vitro* and the phenomenon seems





**Figure 3.** The effect of replacing ARVs with ATV on adiponectin mRNA levels in 3T3-L1 cells. From confluence (day 0), 3T3-L1 cells were treated with differentiation medium in the absence (control) or in the presence of vehicle ( $\square$ ) or various ARVs, which were added to the medium at day 0, when 3T3-L1 cells are still preadipocytes, ( $\circ$ ) (A), or on day 6, when 3T3-L1 cells differentiate to mature adipocytes ( $\circ$ ) (B). On day 7, the cells were washed and then treated with the medium containing ATV ( $\triangle$ ) or with the medium with the same ARV as used until day 7 ( $\circ$ ,  $\circ$ ). On days 7 and 9, total RNA was prepared and mRNA levels were determined by real time RT-PCR. Results shown are after correction for the levels of  $\beta$  actin mRNA and normalized to the control and represent the mean  $\pm$  SE. P values are evaluated by Student's *t*-test. \* $p < 0.01$  versus the same ARV as used until day 7. EFV: efavirenz, RTV: ritonavir, ATV: atazanavir, NFV: nelfinavir

to be caused by several different mechanisms. A greater understanding of the mechanisms underlying the development of this metabolic effect could lead to safer ARVs, and at the same time lead to the most appropriate treatment for these metabolic side effects of ARVs.

#### Acknowledgement

We are grateful to Ms. Mariko Takahashi for her valuable tech-

nical support.

This study was partly supported by Health Science Research Grants on HIV/AIDS from Ministry of Health, Labor and Welfare of Japanese Government. The sponsor had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

#### References

- Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. *Diabetes Care* **29**: 1357-1362, 2006.
- Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. *J Biol Chem* **278**: 40352-40363, 2003.
- Wand H, Calmy A, Carey DL, et al; INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. *AIDS* **21**: 2445-2453, 2007.
- Wohl D, Scherzer R, Heymsfield S, et al; FRAM Study Investigators. The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men. *J Acquir Immune Defic Syndr* **48**: 44-52, 2008.
- Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. *J Acquir Immune Defic Syndr* **45**: 426-431, 2007.
- Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. *Antivir Ther* **9**: 849-863, 2004.
- Lindgaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. *Clin Exp Immunol* **135**: 273-279, 2004.
- Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. *Diabetes Care* **30**: 113-119, 2007 (Erratum in: *Diabetes Care* **30**: 455, 2007).
- Möbius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. *J Acquir Immune Defic Syndr* **39**: 174-180, 2005.



10. Kinlaw WB, Marsh B. Adiponectin and HIV-lipodystrophy: taking HAART. *Endocrinology* **145**: 484-486, 2004.
11. Seoane E, Resino S, Micheloud D, et al. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. *J Acquir Immune Defic Syndr* **48**: 455-459, 2008.
12. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. *Diabetes* **51**: 536-540, 2002 (Erratum in: *Diabetes* **51**: 1294, 2002).
13. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* **257**: 79-83, 1999.
14. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. *J Clin Endocrinol Metab* **86**: 3815-3819, 2001 (Erratum in: *J Clin Endocrinol Metab* **87**: 1626, 2002).
15. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. *Endocrinology* **145**: 2273-2282, 2004.
16. Chaparro J, Reeds DN, Wen W, et al. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. *Metabolism* **54**: 561-567, 2005.
17. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest* **114**: 1752-1761, 2004.

## Human Herpesvirus 8 DNA Load in the Leukocytes Correlates with the Platelet Counts in HIV Type 1-Infected Individuals

Rumi Minami, Masahiro Yamamoto, Soichiro Takahama, Hitoshi Ando,  
 Tomoya Miyamura, and Eiichi Suematsu

### Abstract

Human herpes virus 8 (HHV-8) is known to be reactivated in immunocompromised situations and it is associated with Kaposi's sarcoma (KS) and some hematological diseases. The aim of this study was to analyze the effect of HHV-8 on HIV-1 infection, especially on thrombocytopenia complicated with HIV infection. The HHV-8 DNA load was determined by a quantitative real-time PCR, using leukocytes from 125 HIV-1-infected individuals. HHV-8 DNA was detected in 37 individuals. The increased HIV-1 load and reduced percentage of CD4-positive T cells were significantly associated with the presence of HHV-8. The prevalence and load for HHV-8 are higher in patients with KS than in patients without KS, but the difference is not significant. The increased HHV-8 DNA load was significantly correlated with thrombocytopenia, and platelet counts were significantly lower in individuals with HHV-8 than in individuals without HHV-8. We also obtained the negative correlations between changes in platelet counts and changes in HHV-8 DNA loads. The association between thrombocytopenia and HHV-8 has never been reported previously, apart from some case reports of Castleman's disease and KS. Various cytokines or chemokines are produced by HHV-8-infected cells, some of which have been reported to inhibit hematopoiesis. This may be one of the mechanisms by which HHV-8 infection induces thrombocytopenia. These results indicate that HHV-8 DNA in leukocytes may provide useful information for the assessment of the clinical appearance of HIV-1 infection.

### Introduction

HHV-8, A NEW MEMBER OF THE GAMMAHERPESVIRINAE, was identified as the etiologic agent of Kaposi's sarcoma (KS). The main transmission routes of human herpes virus 8 (HHV-8) seem to be sexual contact,<sup>1</sup> but transmission by saliva,<sup>2</sup> blood products, and organ graft<sup>3,4</sup> has also been proposed. The distribution of HHV-8 is related to a combination of geographic and behavioral risk factors. Serological studies have shown that HHV-8 seroprevalence is high in Africa and the Middle East and low in Europe and the United States. In Japan, it is reported that HHV-8 seroprevalence among healthy controls is 0.2–1.4% and HHV-8 seroprevalence among HIV-1-positive homosexual men is 11.6–63.6%.<sup>5,6</sup>

HHV-8 can infect circulating B cells, monocytes, macrophages, T cells, and KS-like spindle cell progenitors,<sup>7–9</sup> and usually persists in a latent state in these cells. The reactivation of this latent HHV-8 infection can be induced by a number of conditions, including superinfection by other viruses, stress, chronic illnesses, malignancies, and immunosuppressive disorders, such as HIV infection. HHV-8 contains more than

80 open reading frames, including several homologues of oncogenes, cytokine, and cytokine response genes. During latent and lytic infection, some viral genes are expressed and play a causative role in the genesis of some diseases, such as AIDS and non-AIDS-related KS, multicentric Castleman's disease, body cavity-based lymphoma, and some lymphoproliferative diseases. Our previous study reported a case of Castleman's disease with HIV-1 infection in which repeated episodes of thrombocytopenia were correlated with an increase in HHV-8 DNA loads in leukocytes.<sup>10</sup> The aim of this study was to determine the prevalence and loads of HHV-8 DNA in peripheral blood leukocytes in HIV-1-positive individuals and to investigate the correlation with the clinical appearance of HIV-1 infection, especially with thrombocytopenia.

### Materials and Methods

#### *Patients and samples*

All consecutive HIV-1-infected patients who attended Kyushu Medical center between April 2005 and August 2006

were eligible for this study. The exclusion criteria were HCV infection, active hepatitis, and treatment for antihherpes therapy at the time of sampling. Nine HIV-1-positive individuals were analyzed longitudinally before and after the initiation of antiretroviral therapy (ART). For controls, 12 HIV-1-seronegative patients with autoimmune thrombocytopenia and 17 HIV-1-seronegative healthy volunteers were sampled for baseline comparisons. Informed consent for blood sampling was obtained from all participants. The study was conducted according to the ethical guidelines of the hospital and was approved by an authorized representative of the hospital. EDTA-treated blood was taken from the subjects, and leukocytes were collected after removing red blood cells with hemolysis buffer (155 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 0.1 mM EDTA). Cell pellets were stored at -20°C until use.

#### Real-time quantitative PCR

DNA was extracted from the cell pellets using a QIAamp Blood Mini kit (QIAGEN Inc., Tokyo, Japan). Real-time PCR was conducted with the LineGene33 (BioFlux, Tokyo, Japan) using Premix Ex Taq (TAKARA, Shiga, Japan). As an internal control measurement, to normalize for input DNA, copy numbers of  $\beta_2$ -microglobulin ( $\beta_2$ M) were determined in every sample tested. The primers used for amplification were as follows: HHV-8 forward, 5'-CCTCTGGTCCCATTTCATTG-3', and reverse, 5'-CGTTTCCGTCGTGGATGAG-3', and probe 5'-FAM-CCGGCGTCAGACATTCTCACAAACC-TAMRA-3';<sup>11</sup> Epstein-Barr virus (EBV) forward, 5'-CGGAAGCCCTCTGGA CTTC-3', and reverse, 5'-CCCTGTTTATCCGATGGAATG-3', and probe 5'-FAM-TGTACACGCACGAGAAATGCGCC-TAMRA-3';<sup>12</sup>  $\beta_2$ M forward, 5'-CAGCAAGGACTGGTCTTT CTATCTCT-3', and reverse, 5'-ACCCCACTTAACTATCTT GG-3', and probe 5'-FAM-CACTGAAAAAGATGAGTATG CCTGCCGTGT-TAMRA-3'.<sup>13</sup> Standards were obtained by amplification of a control sample in a polymerase chain reaction (PCR) reaction using the same primers. The data were normalized as copies/10<sup>6</sup> cells by measuring copy numbers of the  $\beta_2$ M gene, since two  $\beta_2$ M copy numbers correspond to one cell. The lower limit of detection was defined as 1 copy/10<sup>6</sup> cells.

#### Statistical analyses

Frequency analysis was performed using Fisher's exact test for 2×2 tables. The viral DNA copy numbers of HHV-8, EBV, and HIV-1 were log<sub>10</sub> transformed and compared between different groups by means of the Mann-Whitney *U* test. The associations between them were determined using an analysis of covariance (ANCOVA), with EBV-DNA and HIV-RNA as covariates, where HHV-8 DNA was adjusted on the bases of

EBV-DNA and HIV-RNA. Spearman's rank correlation coefficient was used to compare changes in platelet counts and changes in HHV-8 DNA loads. A partial correlation was used to assess this relationship, while controlling for any changes in HIV-RNA and EBV-DNA.

## Results

#### Subjects characteristics

A total of 125 patients fulfilled the inclusion criteria. Demographic and clinical characteristics of the subjects included in this study are shown in Table 1. There were 8 women and 117 men, 112 of whom were men who have sex with men; the others were heterosexual. These patients were ranged from 20 to 69 years of age (mean age, 37.8 years). Of these, 58 received ART and 67 remained untreated. The duration of ART was 3 months to 9.5 years (mean 3.25 years). Nine HIV-1-positive individuals were analyzed longitudinally before and after the initiation of ART. Among 125 HIV-1-positive subjects included in our study, we evaluated 97 subjects for the prevalence of splenomegaly by means of an abdominal ultrasound examination; 23 subjects were thus found to have splenomegaly.

#### HHV-8 qualitative and quantitative DNA analysis

The presence and load of HHV-8 DNA were investigated in 125 HIV-1-positive subjects and 17 HIV-1-negative healthy controls (Fig. 1). HHV-8 DNA was detected in 37 of 125 (29.6%) leukocyte samples from HIV-1-positive subjects, with values ranging from 2 to 91,171 copies/10<sup>6</sup> leukocytes. HHV-8 DNA was not detected in any healthy controls.

#### Relationship between HHV-8 DNA and KS

HHV-8 DNA was detected in three of five (60%) HIV-infected subjects with KS, whereas they were found in 34 of 120 (28.3%) subjects without KS (*p* = 0.15). Figure 2 shows that the HHV-8 DNA load of subjects with KS to be higher than that of the subjects without KS, but not significantly so.

#### The correlation between HHV-8 DNA and HIV-1-related immunovirological parameters

The HIV-RNA load in the serum of HHV-8 DNA-positive subjects was significantly higher than that of HHV-8 DNA-negative subjects (Fig. 3a). In addition, the correlation between HHV-8 DNA and hypergammaglobulinemia (the percentage of gammaglobulin is more than normal range) was examined, which is often observed in HIV-1-positive subjects. The HHV-8 DNA load in leukocytes in subjects with

TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF 125 HIV-POSITIVE SUBJECTS<sup>a</sup>

	Total	Pretreatment of ART	Treatment of ART	<i>p</i>
<i>N</i> (male/female)	125 (117/8)	67 (63/4)	58 (54/4)	
Age (years)	37.8 ± 10.4	34.3 ± 8.2	42.1 ± 11.2	<0.001
CD4 (cells/ml)	396 ± 218	387 ± 226	407 ± 211	0.616
Viral load (copies/ml) (log <sub>10</sub> )		4.36 ± 0.86	Under detection limit	
Duration of ART (years)		0	3.25 ± 2.68	

<sup>a</sup>The mean values ± SE are shown. Pretreatment of ART versus treatment of ART.




FIG. 1. Quantification of HHV-8 DNA by real-time PCR. Log<sub>10</sub>-transformed HHV-8 copy numbers per 10<sup>6</sup> leukocytes are shown. The bar shows the mean and standard deviations. The dotted line shows the detection limit of the assay.

hypergammaglobulinemia was significantly higher than in subjects without hypergammaglobulinemia (Fig. 3b). HHV-8 DNA was detected in 24 of 44 (54.5%) HIV-infected subjects with hypergammaglobulinemia, whereas it was found in 13 of 81 (16.0%) subjects without hypergammaglobulinemia ( $p < 0.0001$ ). We could not find any significant correlation between HHV-8 DNA loads and CD4-positive T cell counts.

#### The effect of ART on HHV-8 DNA

HHV-8 DNA load in leukocytes in subjects with ART was significantly lower than in subjects without ART (Fig. 4a). HHV-8 DNA was detected in 12 of 58 (20.7%) HIV-infected subjects with ART, whereas it was found in 25 of 67 (37.3%) subjects without ART ( $p = 0.042$ ). There was no difference in the duration of ART between HHV-8 DNA-negative and HHV-8 DNA-positive subjects with ART ( $3.161 \pm 2.764$  vs.  $3.575 \pm 2.439$  years,  $p = 0.624$ ). HHV-8 DNA loads (log<sub>10</sub>) per 10<sup>6</sup> leukocytes in subjects with a short duration of ART (<6 months) were higher than in subjects with a long duration of ART ( $\geq 6$  months), but the difference was not statistically significant ( $0.758 \pm 0.447$  vs.  $0.323 \pm 0.111$ ,  $p = 0.309$ ).




FIG. 2. HHV-8 DNA loads among the HIV-1-positive subjects with or without KS. Log<sub>10</sub>-transformed HHV-8 copy numbers per 10<sup>6</sup> leukocytes are shown. The bar shows the mean and standard deviations.  $p$ -values were estimated by the Mann-Whitney  $U$  test. The dotted line shows the detection limit of the assay.

#### Longitudinal analysis of HHV-8 DNA loads after initiation of ART

The longitudinal profiles of HHV-8 DNA loads were examined in nine subjects after initiation of ART (Fig. 4b). Within 1 month after starting ART, HHV-8 DNA transiently increased in three patients (Fig. 4b, black straight lines); in two of the three patients, KS had progressed transiently. These findings show the reactivation of HHV-8 by initiation of ART. Three months after the initiation of ART, all nine patients had achieved and maintained the decreased levels of HHV-8 DNA.

#### The influence of EBV on HHV-8 infection

Like HHV-8, EBV is lymphotropic and is a member of the gammaherpesvirinae; it is reactivated by HIV-1 infection. Therefore, the influence of EBV on HHV-8 infection was investigated. EBV-DNA loads (log<sub>10</sub>) per 10<sup>6</sup> leukocytes were significantly higher in HHV-8 DNA-positive subjects ( $0.69 \pm 0.11$  vs.  $1.46 \pm 0.21$ ,  $p = 0.0007$ ) and EBV DNA was detected in 32 of 88 (36.4%) HHV-8-negative subjects, whereas they were found in 25 of 37 (67.5%) HHV-8-positive subjects ( $p = 0.002$ ).

#### Relationship between HHV-8 DNA and thrombocytopenia

Figure 5 shows a case of Castleman's disease in which the platelet counts changed in inverse association with HHV-8 DNA in the leukocytes. Therefore, the association between platelet counts and HHV-8 DNA in leukocytes was examined. First, the changes in platelet counts and HHV-8 DNA were analyzed in the nine subjects before and after the initiation of ART (Fig. 6). Both the decrease in HHV-8 DNA and the




FIG. 3. The correlation between HHV-8 DNA and HIV-1-related immunovirological parameters. (a) HIV-RNA loads among the HIV-1-positive subjects with or without HHV-8 DNA. Log<sub>10</sub>-transformed HIV-1 copy numbers/ml of serum are shown. The bar shows the mean and standard deviation. *p*-values were estimated by the Mann-Whitney *U* test. (b) HHV-8 DNA loads among the HIV-1-positive subjects with or without hypergammaglobulinemia. HHV-8 copy numbers per 10<sup>6</sup> leukocytes are shown. The bar shows the mean and standard deviations. *p*-values were estimated by the Mann-Whitney *U* test. The dotted line shows the detection limit of the assay.

increase in platelet counts were significant. Furthermore, the correlation between changes in platelet counts and changes in HHV-8 DNA was obtained (Spearman;  $r = -0.783$ ,  $p = 0.0267$ ). Patients with HIV infection sometimes develop thrombocytopenia, and EBV is also reported to cause mild thrombocytopenia. Therefore, partial correlations were also used to

assess this relationship while controlling for EBV-DNA and HIV-RNA, and the correlation between the change in HHV-8 DNA and platelet counts was obtained (partial correlation coefficient;  $r = -0.733$ ,  $p = 0.0219$ ).

Next, all 125 subjects with HIV infection were analyzed. There was no significant difference between the group with




FIG. 4. The effect of ART on HHV-8 DNA. (a) HHV-8 DNA load in PBMCs in subjects with or without ART. HHV-8 copy numbers per 10<sup>6</sup> leukocytes are shown. The bar shows the mean and standard deviation. *p*-values were estimated by the Mann-Whitney *U* test. (b) HHV-8 DNA load after initiation of ART. HHV-8 DNA loads of the nine subjects were measured at the indicated time points. The dotted line shows the detection limit of the assay.




FIG. 5. Time course of the case of Castleman's disease with HIV-1 infection. Platelet counts,  $\log_{10}$ -transformed HHV-8 and EBV copy numbers per  $10^6$  leukocytes, and  $\log_{10}$ -transformed HIV-1 copy numbers/ml of serum are shown. The data were excerpted from Minami and Yamamoto.<sup>10</sup> PLT, platelet; HHV-8, human herpes virus 8; EBV, Epstein-Barr virus; 3TC, lamivudine; ABC, abacavir; ATV, atazanavir.

thrombocytopenia and the group without thrombocytopenia in terms of the number of subjects with ART, the duration of ART, and the prevalence of subjects with splenomegaly (with thrombocytopenia vs. without thrombocytopenia; 30.8% vs. 22.6%,  $p = 0.520$ ). Similarly, no significant difference was observed between the group with HHV-8-DNA and the group without HHV-8-DNA in terms of the duration of ART and the prevalence of subjects with splenomegaly (with HHV-8 vs. without HHV-8; 26.7% vs. 22.4%,  $p = 0.647$ ). The effects of

HHV-8 DNA in leukocytes on platelet counts were examined using ANCOVA, with EBV-DNA as a covariate. ANCOVA revealed a significant interaction between EBV-DNA and HHV-8 DNA but no significant interaction between thrombocytopenia and EBV-DNA. Post hoc tests revealed that HHV-8 DNA was significantly higher in subjects with platelet counts  $<150,000$  platelets/ $\mu\text{l}$  than in subjects with platelet counts  $\geq 150,000$  platelets/ $\mu\text{l}$  (Fig. 7a). HHV-8 DNA was detected in 11 of 14 (78.6%) subjects with low platelet counts,




FIG. 6. Changes in the platelet counts, HHV-8 DNA loads, EBV-DNA loads, and HIV-RNA of pre- and post-ART. Platelet counts (a), HHV-8-DNA (b), EBV-DNA (c), and HIV-RNA (d) of the nine subjects were analyzed before (pre) and after 2 or 3 months of initiation of ART (post). The viral loads were  $\log_{10}$  transformed. Bar shows the mean and standard deviation.  $p$ -values for the difference between the two time points were estimated by the Wilcoxon signed rank test.




FIG. 7. Relationship between HHV-8 DNA and mild thrombocytopenia. (a) HHV-8 DNA load in leukocytes in subjects with platelet counts of  $<150,000$  platelets/ $\text{mm}^3$  or with platelet counts of  $\geq 150,000$  platelets/ $\text{mm}^3$ . HHV-8 copy numbers per  $10^6$  leukocytes are shown. The bar shows the mean and standard deviation. The  $p$ -values were estimated by a post hoc test after ANCOVA with EBV-DNA as a covariate. (b) Platelet counts among the HIV-1-positive subjects with or without HHV-8 DNA. The bar shows the mean and standard deviation. The  $p$ -values were estimated by a post hoc test after ANCOVA with EBV-DNA as a covariate. The dotted line shows the detection limit of the assay.

whereas it was found in 26 of 111 (23.4%) of subjects with normal platelet counts ( $p=0.0059$ : estimated by post hoc test after ANCOVA with the prevalence of EBV-DNA as a covariate). The platelet counts were lower in HHV-8 DNA-positive subjects than in HHV-8 DNA-negative subjects, but not significantly (Fig. 7b). In subjects without ART, HIV-RNA might be a confounding factor, and thus ANCOVA was conducted with HIV-RNA and EBV-DNA as covariates.

In subjects without ART, HHV-8 DNA was also significantly higher in subjects with mild thrombocytopenia with an adjustment for EBV-DNA and HIV-RNA ( $p=0.013$ , data not shown). HHV-8 DNA was not detected in the 12 subjects with autoimmune thrombocytopenia. We also examined the correlation between HHV-8 DNA loads and platelet counts in subjects without KS, because the subject with KS might have occult Castleman's disease, which can cause thrombocytopenia. HHV-8 DNA was significantly higher in subjects with platelet counts of  $<150,000$  platelets/ $\mu\text{l}$  than in subjects with platelet counts of  $\geq 150,000$  platelets/ $\mu\text{l}$  [ $\log_{10}$  (HHV-8) =  $2.103 \pm 1.797$  vs.  $0.438 \pm 0.924$ ;  $p=0.0285$ ]. HHV-8 DNA was detected in 9 of 12 (75.0%) subjects with low platelet counts, whereas it was found in 25 of 108 (23.1%) subjects with normal platelet counts ( $p=0.0002$ ). The platelet counts were significantly lower in HHV-8 DNA-positive subjects than in HHV-8 DNA-negative subjects ( $21.5 \pm 8.61/\mu\text{l}$  vs.  $25.0 \pm 5.56/\mu\text{l}$ ;  $p=0.1319$ ).

## Discussion

Some previous studies have examined the prevalence of HHV-8 infection in HIV-1-infected subjects. A unique aspect of this study is that the effect of HHV-8 DNA in the peripheral

blood leukocytes on HIV-1 infection was examined; a significant association between HHV-8 DNA and the clinical appearance of HIV-1 infection, especially thrombocytopenia complicated with HIV-1, was found.

Some reports have shown that the presence of KS was associated with the prevalence of HHV-8 DNA in leukocytes<sup>14</sup> and the severity was associated with HHV-8 DNA loads in leukocytes.<sup>15</sup> The current data also showed a certain association with the presence of KS and HHV-8 DNA load, but in this study there were only five subjects with KS, because the prevalence of KS in HIV-1-infected patients in Japan is low. As a result, it was impossible to determine whether the HHV-8 DNA load predicted the onset and severity of KS. To draw any conclusions concerning the clinical and prognostic utility on KS, more subjects with KS need to be analyzed.

HHV-8 encodes homologues of cytokine and cytokine response genes, such as viral interleukin-6 (vIL-6)<sup>16</sup> and viral interferon regulatory factor (vIRF). vIL-6 can bind the gp130 receptor to activate IL-6 response genes and promote B cell activation, which is the mechanism of hypergammaglobulinemia induced by HHV-8 infection. It was also found that HHV-8 plays an important role in hypergammaglobulinemia, which is often found in subjects with HIV-1 infection.

The current data showed that HIV-RNA load in the serum of HHV-8 DNA-positive subjects was significantly higher than that found in the serum of HHV-8 DNA-negative subjects. HHV-8 replication is activated by HIV-Tat,<sup>17</sup> and it has been reported that HHV-8 reactivation is associated with HIV-1 acute infection.<sup>18</sup> Furthermore, an open reading frame (ORF), the major transactivator of the HHV-8 lytic cycle, can also induce increased levels of HIV replication. In conclusion, these findings show that HHV-8 coinfection is associated with



immunological characteristics and disease severity of HIV infection.

ART reduced HHV-8 DNA loads as well as HIV-RNA (Fig. 4). The inhibition of HIV-1 replication with ART probably leads to the reconstitution of the immune system and regenerates effective immune responses against HHV-8. Moreover, protease inhibitors block the production of inflammatory cytokines,<sup>19</sup> which in turn may result in the downregulation of HHV-8 replication. In this longitudinal study during ART, HHV-8 DNA loads transiently increased in three subjects soon after the initiation of ART. This might be due to the disorder of cytokine balance, which occurs transiently in the process of the reconstitution of the immune system, and this might be one of the explanations for the immune reconstitution syndrome of KS. Some inflammatory cytokines are induced in immune reconstitution syndromes. It has recently been reported that some cytokines, which are associated with the development of KS, were elevated in other reconstitution syndromes.<sup>20</sup> It is possible that reactivation of HHV-8 by ART might activate the inflammation of the other reconstitution syndromes by the increase in vIL-6 or other cytokines.

The difference between HHV-8 DNA in the subjects with platelet counts of  $<150,000$  platelets/ $\mu\text{l}$  and in the subjects with platelet counts of  $\geq 150,000$  platelets/ $\mu\text{l}$  was significant, but the difference between the platelet counts in the HHV-8 DNA-positive subjects and the platelet counts in the HHV-8 DNA-negative subjects was not significant. This is because HHV-8 DNA correlates with "mild" thrombocytopenia.

This is the first report that analyzed the association between HHV-8 DNA and thrombocytopenia in HIV-1-infected subjects, though there are a few studies that showed the relationship between HHV-8 infection and hematological disorders<sup>21</sup> or posttransplantation bone marrow failure in HIV-1-negative subjects.<sup>22</sup> Some case reports have described thrombocytopenia complicated with HHV-8-induced Castleman's disease, hemophagocytic syndrome, or other inflammatory syndromes. The HIV-1-positive subjects sometimes develop thrombocytopenia, which has been thought to be caused by an autoimmune mechanism. Recently, antibody cross-reactivity between a known epitope region of HIV-1 proteins and platelet GPIIb/IIIa49-66 has been reported to be responsible for HIV-1-associated thrombocytopenia.<sup>23</sup> However, the present study showed that HHV-8 also contributes independently to the thrombocytopenia complicated in HIV-1 infection.

The molecular mechanism of thrombocytopenia induced by HHV-8 remains to be established, but it is possible that some cytokines or chemokines induced by HHV-8 might be involved in thrombocytopenia. For example, interleukin-8 (IL-8), which is induced by HHV-8 infection,<sup>24</sup> binds the receptors on megakaryocytes and platelets and inhibits megakaryocytopoiesis.<sup>25</sup> Furthermore, HHV-8 is reported to infect CD34-positive hematopoietic progenitor cells<sup>26,27</sup>; HHV-8 harboring CD34-positive cells might also contribute to hematological disorders including thrombocytopenia.<sup>28</sup> Another possible explanation for thrombocytopenia is an autoimmune mechanism such as immune thrombocytopenia (ITP). Chronic stimulation of the B cell clones induced by HHV-8 could favor the production of autoantibodies, some of which might react against platelet. In fact, Evan's syndrome complicating multicentric Castleman's disease<sup>29</sup> and ITP complicating KS have been reported.<sup>30</sup>

In Italy, the area of subendemicity of HHV-8, the presence of HHV-8 DNA in HIV-1-negative elderly people has been reported to be associated with mild thrombocytopenia.<sup>31</sup> In Japan, HHV-8 infection in HIV-1-negative subjects is rare; as a result, when the 12 subjects with autoimmune thrombocytopenia were examined, the association between HHV-8 and autoimmune thrombocytopenia in HIV-1-negative subjects was not distinct. However, the fact that HHV-8 DNA was not detected in the HIV-1-negative subjects with autoimmune thrombocytopenia suggests that HHV-8 is not a main causative agent of autoimmune thrombocytopenia.

In conclusion, a significant association was observed between HHV-8 infection and the clinical appearance of HIV-1 infection, especially in regard to mild thrombocytopenia, hypergammaglobulinemia, and disease severity. It is possible that some of these effects of HHV-8 infection are related to other independent etiological cofactor or some other viruses. However, it may be useful to monitor HHV-8 DNA in leukocytes of HIV-1-positive subjects to assess and predict disease severity and to select the optimal treatment modalities.

#### Acknowledgments

We are grateful to Ms. Asuka Horita and Ms. Mariko Takahashi for their valuable technical support. This study was partly supported by Health Science Research Grants on HIV/AIDS from the Ministry of Health, Labor, and Welfare of the Japanese Government. The sponsor had no role in the study design, data collection, data analysis, and data interpretation, or in the writing of this report.

#### Disclosure Statement

No competing financial interests exist.

#### References

1. Ablashi DV, Chatlynne LG, Whitman JE Jr, and Cesarman E: Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. *Clin Microbiol Rev* 2002; 15:439-464.
2. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, and Kryscio RJ: High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. *J Clin Microbiol* 2006;44:2409-2415.
3. Challine D, Roudot-Thoraval F, Sarah T, *et al.*: Seroprevalence of human herpes virus 8 antibody in populations at high or low risk of transfusion, graft, or sexual transmission of viruses. *Transfusion* 2001;41:1120-1125.
4. Stein L, Carrara H, Norman R, Alagiozoglou L, Morris L, and Sitas F: Antibodies against human herpesvirus 8 in South African renal transplant recipients and blood donors. *Transpl Infect Dis* 2004;6:69-73.
5. Fujii T, Taguchi H, Katano H, *et al.*: Seroprevalence of human herpesvirus 8 in human immunodeficiency virus 1-positive and human immunodeficiency virus 1-negative populations in Japan. *J Med Virol* 1999;57:159-162.
6. Katano H, Iwasaki T, Baba N, *et al.*: Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. *J Virol* 2000;74:3478-3485.

7. Mesri EA, Cesarman E, Arvanitakis L, *et al.*: Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. *J Exp Med* 1996;183:2385–2390.
8. Sirianni MC, Vincenzi L, Topino S, *et al.*: Human herpesvirus 8 DNA sequences in CD8 + T cells. *J Infect Dis* 1997;176:541.
9. Sirianni MC, Uccini S, Angeloni A, Faggioni A, Cottoni F, and Ensoli B: Circulating spindle cells: Correlation with human herpesvirus-8 (HHV-8) infection and Kaposi's sarcoma. *Lancet* 1997;349:255.
10. Minami R and Yamamoto M: A case of HIV-1 and HHV-8-associated Castleman disease with a relapsing high fever and lymphadenopathy. *Kansenshogaku Zasshi* 2006;80:423–427.
11. Polstra AM, Van Den Burg R, Goudsmit J, and Cornelissen M: Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS-associated Kaposi's sarcoma. *J Clin Microbiol* 2003;41:5488–5491.
12. Kimura H, Morita M, Yabuta Y, *et al.*: Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. *J Clin Microbiol* 1999;37:132–136.
13. Nagai H, Wada K, Morishita T, Utsumi M, Nishiyama Y, and Kaneda T: New estimation method for highly sensitive quantitation of human immunodeficiency virus type 1 DNA and its application. *J Virol Methods* 2005;124:157–166.
14. Boivin G, Gaudreau A, Toma E, *et al.*: Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: Correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. *Antimicrob Agents Chemother* 1999;43:377–380.
15. Laney AS, Cannon MJ, Jaffe HW, *et al.*: Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi's sarcoma. *AIDS* 2007;21:1541–1545.
16. Aoki Y, Jones KD, and Tosato G: Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. *J Hematother Stem Cell Res* 2000;9:137–145.
17. Harrington W Jr, Sieczkowski L, Sosa C, *et al.*: Activation of HHV-8 by HIV-1 tat. *Lancet* 1997;349:774–775.
18. Lennette ET, Busch MP, Hecht FM, and Levy JA: Potential herpesvirus interaction during HIV type 1 primary infection. *AIDS Res Hum Retroviruses* 2005;21:869–875.
19. Wasmuth JC, Nischalke HD, Jütte A, *et al.*: Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. *Antiviral Res* 2004;61:207–212.
20. Tamburini J, Grimaldi D, Chiche JD, Bricaire F, and Bossi P: Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients. *AIDS* 2007;21:1980–1983.
21. Tsai WH, Lee YM, Ing-Tiau Kuo B, *et al.*: Increased seroprevalence of human herpesvirus 8 in patients with hematological disorders. *Acta Haematol* 2005;114:95–98.
22. Cuzzola M, Irrera G, Iacopino O, *et al.*: Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation. *Clin Infect Dis* 2003;37:102–106.
23. Li Z, Nardi MA, and Karpatkin S: Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. *Blood* 2005;106:572–576.
24. Sun Q, Matta H, Lu G, and Chaudhary PM: Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation. *Oncogene* 2006;25:2717–2726.
25. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, and Ratajczak MZ: Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: Determination of response to stromal-derived factor-1 by megakaryocytes and platelets. *Br J Haematol* 1999;104:220–229.
26. Henry M, Uthman A, Geusau A, *et al.*: Infection of circulating CD34 + cells by HHV-8 in patients with Kaposi's sarcoma. *J Invest Dermatol* 1999;113:613–616.
27. Wu W, Vieira J, Fiore N, *et al.*: KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: Persistence of infection during hematopoiesis *in vitro* and *in vivo*. *Blood* 2006;108:141–151.
28. Quinn JP, Gilligan OM, and Horgan M: Evans's syndrome complicating multicentric Castleman's disease—dramatic response to rituximab. *Eur J Haematol* 2004;73:384–385.
29. Brown EE, Whitby D, Vitale F, *et al.*: Correlates of human herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma. *Int J Epidemiol* 2005;34:1110–1117.
30. Muela Molinero A, Ballesteros del Rio B, Sandoval Guerra V, and Llor Banos J: Evans syndrome as presentation of multicentric Castleman disease. *Rev Clin Esp* 2003;203:616–617.
31. Toyohama T, Nagasaki A, Miyagi J, *et al.*: Kaposi's sarcoma in a human immunodeficiency virus-negative patient treated with corticosteroid for idiopathic thrombocytopenic purpura. *Intern Med* 2003;42:448–449.

Address reprint requests to:

Rumi Minami  
Internal Medicine, Clinical Research Institute  
National Hospital Organization  
Kyushu Medical Center  
1-8-1 Jigyohama, Chuo-ku  
Fukuoka 810-8563, Japan

E-mail: rrrhh@kyumed.jp

## 臨床

## HAART 時代における HIV 感染者の Th1/Th2 バランス

*Th1/Th2 balance in HIV-infected patients in the HAART era*

古西 満	KONISHI Mitsuru	奈良県立医科大学感染症センター 准教授
善本英一郎	YOSHIMOTO Eiichiro	奈良厚生会病院感染制御室 副院長
宇野 健司	UNO Kenji	奈良県立医科大学感染症センター
小川 拓	OGAWA Taku	奈良県立医科大学感染症センター
忽那 賢志	KUTSUNA Satoshi	奈良県立医科大学感染症センター
中川 智代	NAKAGAWA Chiyo	奈良県立医科大学感染症センター
米川 真輔	YONEKAWA Shinsuke	奈良県立医科大学感染症センター
笠原 敬	KASAHARA Kei	奈良県立医科大学感染症センター
前田 光一	MAEDA Koichi	奈良県立医科大学感染症センター 講師
三笠 桂一	MIKASA Keiichi	奈良県立医科大学感染症センター 教授

## はじめに

ヘルパー T(Th)細胞(CD4陽性細胞)は、サイトカインの産生様式に基づいて機能的に異なる Th1細胞と Th2細胞とに分類することができる。この Th1細胞と Th2細胞とのバランスがさまざまな疾患の病態に関連することが知られており、HIV(human immunodeficiency virus)感染症においても注目されている。

そこで、われわれは HIV 感染者において末梢血 CD4陽性細胞内サイトカインをフローサイトメトリーで測定する方法を用い、HAART(highly active antiretroviral therapy)時代における HIV 感染者の Th1/Th2 バランスの臨床的意義について検討したので、報告する。

## 対象と方法

対象は、本研究への参加同意を得ることができ、6ヵ月以上病状が安定していた HIV 感染者27名とした。平均年齢は41.4歳(25~66歳)、性別は男性24名、女性3名、HIV 感染経路は血液製剤が9名、異性間性的接触が14名、同性間性的接触が4名であった。HIV 感染症の病態は無症候性キャリア(AC: asymptomatic carrier)が19名、AIDS(acquired immunodeficiency syndrome)が8名であり、平均 CD4陽性細胞数は389/ $\mu$ l(11~772/ $\mu$ l)、HIV-RNA 量が50コピー/ml未満の症例は9名、10,000コピー/ml以上の症例は7名であった。19名が抗 HIV 治療を受けていた。

Th1/Th2バランスの評価には、末梢血中の CD4陽

性細胞を phorbol 12-myristate 13-acetate(PMA)と ionomycin で刺激した後に産生された細胞内 interferon(IFN)- $\gamma$ と interleukin(IL)-4をフローサイトメトリーで測定する方法を用いた。IFN- $\gamma$ 陽性 CD4陽性細胞を Th1細胞、IL-4陽性 CD4陽性細胞を Th2細胞とし、その比を Th1/Th2バランスとした。

Th1/Th2比と HIV 感染症の臨床病態、抗 HIV 治療効果および末梢血好酸球数・血清 IgE 値との関連について検討した。抗 HIV 治療を行っている症例(19名)で、末梢血 CD4陽性細胞数が200/ $\mu$ l以上かつ HIV-RNA 量が400コピー/ml未満を3ヵ月以上継続している場合を治療効果良好症例、そうでない場合を治療効果不良症例とした。

統計学的解析には、Student's t-検定および回帰分析を用いた。

**Key words** HIV 感染症 抗 HIV 治療 ヘルパー T細胞 Th1/Th2バランス




図1 CD4 陽性細胞数, CD8 陽性細胞数と Th1/Th2 比との関係

## 結 果

Th1/Th2比の平均値は AC 症例が9.3, AIDS 症例が8.0であり, 有意差はなかった。

Th1/Th2比と末梢血 CD4陽性細胞数とは有意な正の相関 ( $p < 0.01$ ) を認めた。また, 末梢血 CD8陽性細胞数とは有意な弱い正の相関 ( $p < 0.05$ ) があつた (図1)。

Th1/Th2比の平均値は抗 HIV 治療効果良好症例で11.5, 不良症例で5.4であり, 有意差 ( $p < 0.01$ ) を認めた (図2)。

Th1/Th2比と末梢血好酸球数との間には相関はなかった。Th1/Th2比と血清 IgE 値とは有意な負の相関 ( $p < 0.05$ ) を認めた (図3)。

## 考 察

Th 細胞は免疫系の特異的の反応を司り, サイトカイン産生細胞としてきわめて重要な細胞である。Mosmann ら<sup>1)</sup>は, 産生するサイトカインの種類で Th 細胞には二つの亜集団, すなわち, 主に細胞性免疫機構を活性化する IL-2や IFN- $\gamma$ を産生する Th1細胞と, 主に液性免疫機構を活性化する IL-4, IL-5, IL-10を産生する Th2細胞が存在することを報告している。その後の研究から, Th1細胞と Th2細胞のバランスが感染症, 自己免疫疾患, アレルギーなどの発症や病態形成に関与すると考えられている<sup>2)</sup>。

HIV 感染症は IFN- $\gamma$ を産生する Th 細胞が減少し, 細胞性免疫障害を生じる疾患である。また, 1990年代




図2 HAART の臨床的効果と Th1/Th2 比との関係

初めには, Th 細胞が Th1細胞から Th2細胞にスイッチすることが HIV 増幅をもたらし, HIV 感染症の病状を進行させる<sup>3)</sup>という仮説が出されている。しかし, この理論には反論も多く, いまだに結論は得られていない。Imami ら<sup>4)</sup>は, 長期非進行性 HIV 感染者では Th2細胞の活性化も強く, Th1細胞と Th2細胞間の適正な調節が HIV 増幅抑制に重要であると推察している。

一方, 1990年代後半から HAART が導入され, その有用性については数多くの報告がなされている<sup>5)6)</sup>。




図3 末梢血好酸球数, 血清 IgE 値と Th1/Th2 比との関係

ところが, HAART 時代における HIV 感染者の Th1/Th2 バランスに関する臨床的な検討は少ない. そこで, われわれは少数例ではあるがその解析を行い, 病状の安定した HIV 感染者では AIDS 発症の有無は Th1/Th2 比と関連はないが, 現時点の末梢血 CD4 陽性細胞数や治療効果が良好な症例では Th1/Th2 比が高くなっていることが見い出せた. Reuben ら<sup>7)</sup>は, 小児例ではあるが, HAART によって IFN- $\gamma$  産生能が回復することを報告しているが, 同時に HAART によって IL-10 産生能も高くなっていることを指摘している. したがって, HAART によって Th1 細胞, Th2 細胞とも回復するが, 病態の良好な症例では Th1 細胞の回復がより勝っている可能性があると考えられる.

今回の検討では, Th1/Th2 比と血清 IgE 値とは有意な負の相関を認めたことから, 血清 IgE 値が簡易な Th1/Th2 比の臨床的指標となる可能性が示唆される. HIV 感染者で高 IgE 血症を呈する症例があることは古くから指摘され, 血清 IgE 値と臨床病態に関連が

ある<sup>8)</sup>ことが報告されている. また, HIV 感染者において血清 IgE 値と IL-4 や IL-10 には正の相関あることや, IFN- $\gamma$  や IL-12P70 には負の相関を認める<sup>9)10)</sup>ことも報告されている. さらに, HIV-1 の gp120 がアレルゲンとして働き, IL-4 産生を誘導して IgE 合成をもたらす<sup>11)</sup>ことも指摘されており, HAART によるウイルス量減少が Th1/Th2 比に影響する機序の一つである可能性が考えられる.

したがって, HAART 時代においても HIV 感染者の Th1/Th2 バランスを評価することは意義があり, 血清 IgE 値がその指標の一つとなる可能性があると考えられる.

#### 謝 辞

本研究の要旨は, 第21回近畿エイズ研究会(2007年6月, 会長奥野良信先生)で発表し, 近畿エイズ研究会学術賞(理事長生田和良教授)を賜りましたことに心から感謝申し上げます.

#### 文 献

- 1) Mosmann TR, Cherwinski H, Bond MW, et al: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 136: 2348-2357, 1986.
- 2) Kidd P: Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. *Altern Med Rev* 8: 223-246, 2003.
- 3) Cleric M, Shearer GM: A Th1 $\rightarrow$ Th2 switch is a critical step in etiology of HIV infection. *Immunol Today* 14: 107-111, 1993.
- 4) Imami N, Pires A, Hardy G, et al: A balanced type1/type2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. *J Virol* 76: 9011-9023, 2002.
- 5) Lohse N, Hansen AB, Pedersen G, et al: Survival of persons with and without HIV infection in Denmark, 1995-2005. *Ann Intern Med* 146: 87-95, 2007.
- 6) Robert WB, Darrell HST: Prolongation and quality of life for HIV-infected adults treated with